PDS Planning Inc Purchases 182 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

PDS Planning Inc boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,426 shares of the biopharmaceutical company’s stock after buying an additional 182 shares during the quarter. PDS Planning Inc’s holdings in Gilead Sciences were worth $359,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. OFI Invest Asset Management purchased a new position in shares of Gilead Sciences in the third quarter valued at about $26,000. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $29,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $40,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.31 during mid-day trading on Tuesday, hitting $67.26. 1,553,676 shares of the stock were exchanged, compared to its average volume of 7,254,602. The firm has a fifty day moving average of $71.81 and a 200 day moving average of $76.51. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86. The company has a market cap of $83.74 billion, a PE ratio of 14.88, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.67 earnings per share. Research analysts anticipate that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.58%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on GILD shares. Cantor Fitzgerald reduced their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Wells Fargo & Company reduced their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Mizuho reduced their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. StockNews.com cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average target price of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.